Malignant Mixed Ovarian Germ Cell Tumor Composed of Immature Teratoma, Yolk Sac Tumor and Embryonal Carcinoma Harboring an EGFR Mutation: a Case Report

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2018 Oct 24

PMID 30349318

Authors

Yao Wang

Jia-Xin Yang

Mei Yu

Dong-Yan Cao

Keng Shen

Affiliations

Soon will be listed here.

Abstract

Malignant mixed ovarian germ cell tumors are very rare, accounting for ~5.3% of all malignant ovarian germ cell tumors (MOGCTs), with a very high degree of malignancy. The treatment of patients with persistent, refractory, or platinum-resistant MOGCT is not well defined. The objective of this case report was to analyze the importance of chemotherapy, salvage surgery and target therapy in the treatment of a patient with refractory OGCT after first-line chemotherapy failure. We reported a 34 year-old woman suffered from advanced refractory MOGCT after first-line chemotherapy, cytoreductive surgery, and a series of chemotherapy. The genetic test shows she is a carrier of EGFR: p.L858R mutation. Based on genetic testing result, she received icotinib which targeted for EGFR mutation, but the tumor progressed. After a secondary cytoreductive surgery, she exhibited a partial response and continued to receive chemotherapy. This suggests that salvage surgery may be considered for patients with persistent or refractory MOGCTs when no effective systemic treatment option is available. Targeted therapies based on gene sequencing may provide a new option; however, its efficacy and related resistance mechanisms still need to be verified by further study.

References

Mishra R, Hanker A, Garrett J . Genomic alterations of ERBB receptors in cancer: clinical implications. Oncotarget. 2018; 8(69):114371-114392. PMC: 5768410. DOI: 10.18632/oncotarget.22825. View

Ishiguro T, Yoshida Y, Tenzaki T, Ohshima M, Suzuki H . AFP in yolk sac tumor and solid teratoma of the ovary: significance of postoperative serum AFP. Cancer. 1981; 48(11):2480-4. DOI: 10.1002/1097-0142(19811201)48:11<2480::aid-cncr2820481122>3.0.co;2-8. View

Ghalleb M, Bouzaiene H, Slim S, Hadiji A, Hechiche M, Ben Hassouna J . Fertility-sparing surgery in advanced stage malignant ovarian germ cell tumor: a case report. J Med Case Rep. 2017; 11(1):350. PMC: 5733088. DOI: 10.1186/s13256-017-1516-8. View

Lai C, Chang T, Hsueh S, Wu T, Chao A, Chou H . Outcome and prognostic factors in ovarian germ cell malignancies. Gynecol Oncol. 2005; 96(3):784-91. DOI: 10.1016/j.ygyno.2004.11.027. View

Werness B, Ramus S, Whittemore A, Garlinghouse-Jones K, Oakley-Girvan I, DiCioccio R . Primary ovarian dysgerminoma in a patient with a germline BRCA1 mutation. Int J Gynecol Pathol. 2000; 19(4):390-4. DOI: 10.1097/00004347-200010000-00017. View

Eastham J, Wilson T, Russell C, Ahlering T, SKINNER D . Surgical resection in patients with nonseminomatous germ cell tumor who fail to normalize serum tumor markers after chemotherapy. Urology. 1994; 43(1):74-80. DOI: 10.1016/s0090-4295(94)80269-6. View

Smith H, Berwick M, Verschraegen C, Wiggins C, Lansing L, Muller C . Incidence and survival rates for female malignant germ cell tumors. Obstet Gynecol. 2006; 107(5):1075-85. DOI: 10.1097/01.AOG.0000216004.22588.ce. View

Gershenson D, Morris M, Cangir A, Kavanagh J, Stringer C, Edwards C . Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin. J Clin Oncol. 1990; 8(4):715-20. DOI: 10.1200/JCO.1990.8.4.715. View

Nishimura T, Nakamura K, Yamashita S, Ikeda S, Kigure K, Minegishi T . Effect of the molecular targeted drug, erlotinib, against endometrial cancer expressing high levels of epidermal growth factor receptor. BMC Cancer. 2015; 15:957. PMC: 4682234. DOI: 10.1186/s12885-015-1975-5. View

10.

Zhao Q, Yang J, Cao D, Han J, Xu K, Liu Y . Tailored therapy and long-term surveillance of malignant germ cell tumors in the female genital system: 10-year experience. J Gynecol Oncol. 2016; 27(3):e26. PMC: 4823357. DOI: 10.3802/jgo.2016.27.e26. View

11.

Cheng L, Roth L, Zhang S, Wang M, Morton M, Zheng W . KIT gene mutation and amplification in dysgerminoma of the ovary. Cancer. 2011; 117(10):2096-103. DOI: 10.1002/cncr.25794. View

12.

Witkowski L, Mattina J, Schonberger S, Murray M, Choong C, Huntsman D . DICER1 hotspot mutations in non-epithelial gonadal tumours. Br J Cancer. 2013; 109(10):2744-50. PMC: 3833222. DOI: 10.1038/bjc.2013.637. View

13.

Gershenson D . Management of ovarian germ cell tumors. J Clin Oncol. 2007; 25(20):2938-43. DOI: 10.1200/JCO.2007.10.8738. View

14.

Chan J, Tewari K, Waller S, Cheung M, Shin J, Osann K . The influence of conservative surgical practices for malignant ovarian germ cell tumors. J Surg Oncol. 2008; 98(2):111-6. PMC: 4111627. DOI: 10.1002/jso.21079. View

15.

Lee S, Kim K, Kim S, Lee N, Park H, Won J . Mixed testicular germ cell tumor presenting as metastatic pure choriocarcinoma involving multiple lung metastases that was effectively treated with high-dose chemotherapy. Cancer Res Treat. 2010; 41(4):229-32. PMC: 2802842. DOI: 10.4143/crt.2009.41.4.229. View

16.

Milewska M, Cremona M, Morgan C, OShea J, Carr A, Vellanki S . Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers. Ther Adv Med Oncol. 2018; 10:1758834017746040. PMC: 5784557. DOI: 10.1177/1758834017746040. View

17.

Ueda G, Abe Y, Yoshida M, Fujiwara T . Embryonal carcinoma of the ovary: a six-year survival. Int J Gynaecol Obstet. 1990; 31(3):287-92. DOI: 10.1016/0020-7292(90)91025-l. View

18.

Shaaban A, Rezvani M, Elsayes K, Baskin Jr H, Mourad A, Foster B . Ovarian malignant germ cell tumors: cellular classification and clinical and imaging features. Radiographics. 2014; 34(3):777-801. DOI: 10.1148/rg.343130067. View

19.

De Giorgi U, Richard S, Badoglio M, Kanfer E, Bourrhis J, Nicolas-Virelizier E . Salvage high-dose chemotherapy in female patients with relapsed/refractory germ-cell tumors: a retrospective analysis of the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol. 2017; 28(8):1910-1916. DOI: 10.1093/annonc/mdx259. View

20.

Adra N, Einhorn L, Althouse S, Ammakkanavar N, Musapatika D, Albany C . Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206. Ann Oncol. 2017; 29(1):209-214. DOI: 10.1093/annonc/mdx680. View